Amgen Pays $71M To 47 States To Settle Aranesp, Enbrel Off-Label Claims

(August 19, 2015, 9:31 AM EDT) -- Amgen Inc. has agreed to pay $71 million to 47 states and the District of Columbia to settle state court claims that the drug maker violated state consumer protection laws by promoting the anemia drugs Aranesp and Enbrel for off-label uses, according to Aug. 18 press releases from several of the states.

(Connecticut complaint and judgment available. Document #28-150820-009C.)

According to a press release from the New York Attorney General’s Office, the states filed complaints and consent judgments in their respective state courts alleging that in...
To view the full article, register now.